ID

13768

Descrizione

A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis; ODM derived from: https://clinicaltrials.gov/show/NCT01433250

collegamento

https://clinicaltrials.gov/show/NCT01433250

Keywords

versioni (2)
  1. 06/03/16 06/03/16 -
  2. 20/09/21 20/09/21 -
Caricato su

6 marzo 2016

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Multiple Sclerosis NCT01433250

Inglese

Eligibility Multiple Sclerosis NCT01433250

1 moduli  
Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. was exposed to ain457 or placebo in study cain457b2201 and completed the cain457b2201 study, up to at and including visit 10 (week 24).
Descrizione

ain457; placebo

Tipo di dati

boolean

Alias
UMLS CUI [1]
C3179548
UMLS CUI [2]
C1696465
Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. have been treated with:
Descrizione

therapy

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0087111
immunosuppressive medications such as azathioprine or methotrexate within 1 month prior to enrollment, if lymphocyte count normal.
Descrizione

Immunosuppressive Agents; azathioprine; methotrexate

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0021081
UMLS CUI [2]
C0004482
UMLS CUI [3]
C0025677
immunoglobulins and/or monoclonal antibodies (with the exception of ain457) within 2 month prior to enrollment, or if the immunosuppressive effects are likely to persist at enrollment (such as presence of b cell depletion after rituximab treatment).
Descrizione

immunoglobulins; monoclonal antibodies; b lymphocyte depletion therapy; rituximab

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0021027
UMLS CUI [2]
C0003250
UMLS CUI [3]
C1171324
UMLS CUI [4]
C0393022
2. have received total lymphoid irradiation, bone marrow transplantation, alemtuzumab, cladribine, cyclophosphamide, mitoxantrone or other immunosuppressive treatments with long-lasting (over 6 months) or permanent effects.
Descrizione

Lymphatic Irradiation; alemtuzumab; cladribine; cyclophosphamide; mitoxantrone

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0024230
UMLS CUI [2]
C0383429
UMLS CUI [3]
C0092801
UMLS CUI [4]
C0010583
UMLS CUI [5]
C0026259
3. have received any live or live attenuated vaccines (including live vaccines for varicella-zoster virus or measles) within 2 months prior to enrollment.
Descrizione

Vaccines, Attenuated; measles vaccines ; Varicella-zoster vaccine

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0042211
UMLS CUI [2]
C2064743
UMLS CUI [3]
C1319755
4. a diagnosis of chronic disease of the immune system other than ms, or of an immunodeficiency syndrome.
Descrizione

Chronic disease of immune system; immunodeficiency syndrome

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1290894
UMLS CUI [2]
C0021051
5. current severe depression.
Descrizione

severe depression

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0588008
6. pregnant or nursing (lactating) women.
Descrizione

pregnancy; lactating

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
7. malignancy diagnosed since enrollment in the core study (except for successfully-treated basal or squamous cell carcinoma of skin).
Descrizione

malignancy; squamous cell carcinoma of skin

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0006826
UMLS CUI [2]
C0553723
8. a new diagnosis of diabetes
Descrizione

diabetes

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0011849
9. positive testing for tuberculosis (quantiferon or chest x-ray).
Descrizione

tuberculosis test

Tipo di dati

boolean

Alias
UMLS CUI [1]
C2242734
10. subjects with clinically significant cardiac abnormalities
Descrizione

cardiac abnormalities

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0018798
11. unable or unwilling to undergo multiple venipunctures
Descrizione

venipunctures

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0600406
12. unable to undergo mri scans due to newly acquired claustrophobia or metallic implants incompatible with mri.
Descrizione

mri; claustrophobia ; metallic implant

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0024485
UMLS CUI [2]
C0008909
UMLS CUI [3]
C3693688
other protocol-defined inclusion/exclusion criteria may apply
Descrizione

inclusion; exclusion criteria

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1512693
UMLS CUI [2]
C0680251
Ritorna all'inizio della pagina

Similar models

Eligibility Multiple Sclerosis NCT01433250

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
ain457; placebo
Item
1. was exposed to ain457 or placebo in study cain457b2201 and completed the cain457b2201 study, up to at and including visit 10 (week 24).
boolean
C3179548 (UMLS CUI [1])
C1696465 (UMLS CUI [2])
Item Group
C0680251 (UMLS CUI)
therapy
Item
1. have been treated with:
boolean
C0087111 (UMLS CUI [1])
Immunosuppressive Agents; azathioprine; methotrexate
Item
immunosuppressive medications such as azathioprine or methotrexate within 1 month prior to enrollment, if lymphocyte count normal.
boolean
C0021081 (UMLS CUI [1])
C0004482 (UMLS CUI [2])
C0025677 (UMLS CUI [3])
immunoglobulins; monoclonal antibodies; b lymphocyte depletion therapy; rituximab
Item
immunoglobulins and/or monoclonal antibodies (with the exception of ain457) within 2 month prior to enrollment, or if the immunosuppressive effects are likely to persist at enrollment (such as presence of b cell depletion after rituximab treatment).
boolean
C0021027 (UMLS CUI [1])
C0003250 (UMLS CUI [2])
C1171324 (UMLS CUI [3])
C0393022 (UMLS CUI [4])
Lymphatic Irradiation; alemtuzumab; cladribine; cyclophosphamide; mitoxantrone
Item
2. have received total lymphoid irradiation, bone marrow transplantation, alemtuzumab, cladribine, cyclophosphamide, mitoxantrone or other immunosuppressive treatments with long-lasting (over 6 months) or permanent effects.
boolean
C0024230 (UMLS CUI [1])
C0383429 (UMLS CUI [2])
C0092801 (UMLS CUI [3])
C0010583 (UMLS CUI [4])
C0026259 (UMLS CUI [5])
Vaccines, Attenuated; measles vaccines ; Varicella-zoster vaccine
Item
3. have received any live or live attenuated vaccines (including live vaccines for varicella-zoster virus or measles) within 2 months prior to enrollment.
boolean
C0042211 (UMLS CUI [1])
C2064743 (UMLS CUI [2])
C1319755 (UMLS CUI [3])
Chronic disease of immune system; immunodeficiency syndrome
Item
4. a diagnosis of chronic disease of the immune system other than ms, or of an immunodeficiency syndrome.
boolean
C1290894 (UMLS CUI [1])
C0021051 (UMLS CUI [2])
severe depression
Item
5. current severe depression.
boolean
C0588008 (UMLS CUI [1])
pregnancy; lactating
Item
6. pregnant or nursing (lactating) women.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
malignancy; squamous cell carcinoma of skin
Item
7. malignancy diagnosed since enrollment in the core study (except for successfully-treated basal or squamous cell carcinoma of skin).
boolean
C0006826 (UMLS CUI [1])
C0553723 (UMLS CUI [2])
diabetes
Item
8. a new diagnosis of diabetes
boolean
C0011849 (UMLS CUI [1])
tuberculosis test
Item
9. positive testing for tuberculosis (quantiferon or chest x-ray).
boolean
C2242734 (UMLS CUI [1])
cardiac abnormalities
Item
10. subjects with clinically significant cardiac abnormalities
boolean
C0018798 (UMLS CUI [1])
venipunctures
Item
11. unable or unwilling to undergo multiple venipunctures
boolean
C0600406 (UMLS CUI [1])
mri; claustrophobia ; metallic implant
Item
12. unable to undergo mri scans due to newly acquired claustrophobia or metallic implants incompatible with mri.
boolean
C0024485 (UMLS CUI [1])
C0008909 (UMLS CUI [2])
C3693688 (UMLS CUI [3])
inclusion; exclusion criteria
Item
other protocol-defined inclusion/exclusion criteria may apply
boolean
C1512693 (UMLS CUI [1])
C0680251 (UMLS CUI [2])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial